Humacyte, Inc. (HUMAW) Financials
HUMAW Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 149.4 million | 112.4 million |
2023-06-30 | 168.1 million | 107.0 million |
2023-03-31 | 183.0 million | 101.1 million |
2022-12-31 | 204.3 million | 87.4 million |
HUMAW Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -13.5 million | 1.8 million |
2023-06-30 | -23.1 million | 1.8 million |
2023-03-31 | -19.8 million | 1.8 million |
2022-12-31 | -19.6 million | 1.7 million |
HUMAW Net Income
No data available :(
HUMAW Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 100.0 million | - | 19.5 million |
2023-06-30 | 114.6 million | - | 20.1 million |
2023-03-31 | 131.7 million | - | 18.3 million |
2022-12-31 | 151.9 million | - | 18.9 million |
HUMAW Shares Outstanding
HUMAW Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 493000 | 18.6 million | 6.1 million | - |
2023-06-30 | 485000 | 20.5 million | 3.1 million | - |
2023-03-31 | 1.2 million | 17.3 million | 5.2 million | - |
2022-12-31 | 681000 | 15.0 million | 5.8 million | - |
HUMAW Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | 1.3 million |
2023-06-30 | - | 2.0 million |
2023-03-31 | - | 2.1 million |
2022-12-31 | - | 2.1 million |
HUMAW
Price: $0.69
52 week price:
Earnings Per Share: -3.16 USD
P/E Ratio: -0.17
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 31189
Market Capitalization: 385.7 million